出典: meddic


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/09/12 00:43:40」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Response to "Clinical Relevance of CYP3A5 Genotype on Maraviroc Exposures".
  • Lu Y1, Fuchs EJ1, Hendrix CW1, Bumpus NN2.
  • Drug metabolism and disposition: the biological fate of chemicals.Drug Metab Dispos.2015 May;43(5):773. doi: 10.1124/dmd.115.064188.
  • PMID 25838403
  • Clinical Relevance of CYP3A5 Genotype on Maraviroc Exposures.
  • Vourvahis M1, McFadyen L2, Heera J2, Clark A2.
  • Drug metabolism and disposition: the biological fate of chemicals.Drug Metab Dispos.2015 May;43(5):771-2. doi: 10.1124/dmd.115.063321.
  • PMID 25838402
  • Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients.
  • Ceresola ER1, Nozza S2, Sampaolo M3, Pignataro AR3, Saita D3, Ferrarese R3, Ripa M2, Deng W4, Mullins JI4, Boeri E3, Tambussi G2, Toniolo A5, Lazzarin A6, Clementi M1, Canducci F7.
  • The Journal of antimicrobial chemotherapy.J Antimicrob Chemother.2015 May;70(5):1391-5. doi: 10.1093/jac/dku573. Epub 2015 Jan 20.
  • OBJECTIVES: Although founder viruses in primary HIV-1 infections (PHIs) typically use the CCR5 coreceptor (R5-tropic), 3%-19% of subjects also harbour CXCR4-using viruses (X4-tropic), making tropism determination before CCR5 antagonist usage mandatory. Genotypic methods can be used to accurately det
  • PMID 25608585


  • Impact of maraviroc-resistant mutation M434I in the C4 region of HIV-1 gp120 on sensitivity to antibody-mediated neutralization
  • Boonchawalit Samatchaya,Harada Shigeyoshi,Shirai Noriko,Gatanaga Hiroyuki,Oka Shinichi,Matsushita Shuzo,Yoshimura Kazuhisa
  • Japanese Journal of Infectious Diseases advpub(0), 2015
  • … We previously reported that a maraviroc (MVC) resistant HIV-1 generated using in vitro selection exhibited high sensitivity to several neutralizing monoclonal antibodies (NMAbs) and autologous plasma IgGs. …
  • NAID 130005086979
  • ケモカイン標的療法
  • 義江 修
  • 日本臨床免疫学会会誌 = Japanese journal of clinical immunology 36(4), 189-196, 2013-08-31
  • … を動物実験から見極めることを困難にし,また候補薬物の前臨床試験を動物で行うことを困難にしている.そのため,ケモカインレセプターを標的とした薬剤開発の可能性はいまだ十分に見極められたとは言い難い.本稿では,それぞれのケモカインレセプターの疾患関連性を検討し,さらに実際に現在臨床応用に至っているCCR5阻害薬(Maraviroc),CXCR4阻害薬(Plerixafor),抗CCR4抗体(Mogamulizmab)について紹介したい. …
  • NAID 10031196415
  • インテグラーゼ阻害薬,CCR5受容体拮抗薬 (特集 抗ウイルス薬) -- (抗ウイルス薬の特性と適応・使い分け)


Before taking maraviroc, tell your doctor and pharmacist if you are allergic to maraviroc, any other medications, or any of the ingredients in maraviroc tablets. Ask your pharmacist or check the Medication Guide for a list of ...
SELZENTRY-the only CCR5 antagonist. ... CONTRAINDICATION SELZENTRY is contraindicated in patients with severe renal impairment (CrCl 30 mL/min) or end-stage renal disease (ESRD) who are taking potent cytochrome P450 ...